{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Hikal Ltd is Rated Strong Sell
Hikal Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 23 March 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.
Markets Rally, But Hikal Ltd Sinks to 52-Week Low in Stock-Specific Sell-Off
Hikal Ltd’s share price declined sharply to hit a new 52-week low of Rs.162.5 on 23 March 2026, marking a significant drop amid broader sectoral and market weakness. The stock underperformed both its Pharmaceuticals & Biotechnology sector and the wider market, reflecting ongoing pressures on the company’s financial and technical indicators.
Hikal Ltd Stock Falls to 52-Week Low of Rs.165.45 Amid Sector and Market Downturn
Hikal Ltd’s shares declined sharply to a fresh 52-week low of Rs.165.45 on 19 Mar 2026, marking a significant drop amid a broader sector and market downturn. The stock underperformed the Pharmaceuticals & Biotechnology sector, reflecting ongoing pressures on the company’s financial and technical indicators.
Hikal Ltd Stock Falls to 52-Week Low of Rs.166 Amidst Continued Downtrend
Hikal Ltd’s shares touched a fresh 52-week low of Rs.166 today, marking a significant decline amid persistent downward momentum. The stock’s performance over the past year has been notably weak, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector.
Hikal Ltd Stock Falls to 52-Week Low of Rs.169.1 Amidst Continued Downtrend
Hikal Ltd’s share price declined to a fresh 52-week low of Rs.169.1 today, marking a continuation of the stock’s downward trajectory amid broader sector underperformance and persistent financial headwinds.
Hikal Ltd is Rated Strong Sell
Hikal Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Hikal Ltd Stock Falls to 52-Week Low of Rs.172.8 Amidst Continued Downtrend
Hikal Ltd’s share price declined sharply to a new 52-week low of Rs.172.8 today, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical and biotechnology company’s shares have now fallen for six consecutive sessions, cumulatively losing 13.81% over this period, reflecting persistent pressures on the stock amid broader market weakness.
Hikal Ltd is Rated Strong Sell
Hikal Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 Nov 2025. However, the analysis and financial metrics presented here reflect the company’s current position as of 01 March 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.
Hikal Ltd is Rated Strong Sell
Hikal Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 Nov 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 18 February 2026, providing investors with the latest insights into its performance and outlook.
Hikal Ltd Surges 18.82% Amid Volatility and Strong Volume Despite Sell Rating
Hikal Ltd delivered a remarkable weekly performance, surging 18.82% from Rs.179.55 to Rs.213.35 between 9 and 13 February 2026, significantly outperforming the Sensex, which declined 0.54% over the same period. The stock’s rally was marked by strong volume spikes, intraday volatility, and a notable divergence from broader market trends despite a recent downgrade to a Strong Sell rating by MarketsMOJO.
Has Hikal Ltd declared dividend?
Yes, Hikal Ltd has declared a dividend of 10% (0.8 per share) with an ex-date of February 17, 2026. Despite the dividend, the company has experienced significant price declines over various periods, resulting in modest total returns.
Are Hikal Ltd latest results good or bad?
Hikal Ltd's latest results are concerning, showing a 29.68% year-on-year decline in net sales and a net loss of ₹34.90 crores, marking the second consecutive quarter of losses and indicating significant operational challenges. The company's profitability and return metrics have also sharply declined, reflecting ongoing financial distress.
Hikal Ltd Surges on Exceptional Volume Amid Strong Sell Rating
Hikal Ltd witnessed a remarkable surge in trading volume and price on 12 Feb 2026, emerging as one of the most actively traded stocks in the Pharmaceuticals & Biotechnology sector. Despite a broader market downturn, the stock outperformed its sector and benchmark indices, signalling strong investor interest and potential accumulation amidst volatility.
Hikal Ltd Hits Intraday High with 10.75% Surge on 12 Feb 2026
Hikal Ltd recorded a robust intraday performance on 12 Feb 2026, surging to a day’s high of Rs 210.5, marking a significant 10.75% gain. The stock outperformed its Pharmaceuticals & Biotechnology sector peers and demonstrated heightened volatility throughout the trading session.
Hikal Ltd Q3 FY26: Recovery Masks Deeper Margin Concerns
Hikal Ltd., a speciality chemicals and active pharmaceutical ingredients manufacturer, swung back to operating profit in Q3 FY26 with ₹82.70 crores, yet the company posted a net loss of ₹5.90 crores as elevated interest and depreciation costs overwhelmed the operational recovery. The ₹2,577-crore market cap company's shares have declined 39.05% over the past year, significantly underperforming the Sensex's 8.52% gain and the pharmaceuticals sector's 4.78% advance.
Are Hikal Ltd latest results good or bad?
Hikal Ltd's latest results are concerning, showing a 29.68% year-on-year decline in net sales and a net loss of ₹34.90 crores, indicating significant operational challenges and a stark reversal from previous performance.
Hikal Ltd Falls 6.94% Amidst Persistent Downtrend and Volatile Week
Hikal Ltd’s shares declined by 6.94% over the week ending 6 February 2026, closing at Rs.179.55, significantly underperforming the Sensex which gained 1.51% during the same period. The stock hit fresh 52-week lows twice this week amid continued financial pressures and weak earnings, despite a brief intraday recovery on 3 February. This review analyses the key events and market dynamics shaping Hikal’s performance over the past five trading sessions.
Hikal Ltd is Rated Strong Sell
Hikal Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 07 February 2026, providing investors with the latest insights into the company’s performance and outlook.
Hikal Ltd Stock Falls to 52-Week Low of Rs.180.6 Amid Continued Downtrend
Hikal Ltd’s shares declined sharply to a fresh 52-week low of Rs.180.6 on 6 February 2026, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical and biotechnology company’s stock has underperformed its sector and broader market indices, reflecting persistent financial headwinds and subdued performance metrics.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
